Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Breast Cancer

  Free Subscription


Articles published in Eur J Cancer

Retrieve available abstracts of 59 articles:
HTML format



Single Articles


    September 2021
  1. HAN MG, Jang BS, Kang MH, Na D, et al
    PI3Kgammadelta inhibitor plus radiation enhances the antitumour immune effect of PD-1 blockade in syngenic murine breast cancer and humanised patient-derived xenograft model.
    Eur J Cancer. 2021;157:450-463.
    PubMed     Abstract available


    August 2021
  2. CRISCITIELLO C, Marra A, Morganti S, Zagami P, et al
    Clinical outcomes of patients with metastatic breast cancer enrolled in phase I clinical trials.
    Eur J Cancer. 2021;157:40-49.
    PubMed     Abstract available


  3. MOBUS V, Luck HJ, Ladda E, Klare P, et al
    Phase III randomised trial comparing intense dose-dense chemotherapy to tailored dose-dense chemotherapy in high-risk early breast cancer (GAIN-2).
    Eur J Cancer. 2021;156:138-148.
    PubMed     Abstract available


  4. KAHAN Z, Gil-Gil M, Ruiz-Borrego M, Carrasco E, et al
    Health-related quality of life with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor-positive metastatic breast cancer: Patient-reported outcomes in the PEARL study.
    Eur J Cancer. 2021;156:70-82.
    PubMed     Abstract available


    July 2021
  5. VRIELING C, Assele SY, Moser L, Sauve N, et al
    The impact of isolated local recurrence on long-term outcome in early-breast cancer patients after breast-conserving therapy.
    Eur J Cancer. 2021;155:28-37.
    PubMed     Abstract available


  6. LEFRERE H, Floris G, Schmidt MK, Neven P, et al
    Breast cancer diagnosed in the post-weaning period is indicative for a poor outcome.
    Eur J Cancer. 2021;155:13-24.
    PubMed     Abstract available


  7. HE J, Fu F, Wang W, Xi G, et al
    Prognostic value of tumour-infiltrating lymphocytes based on the evaluation of frequency in patients with oestrogen receptor-positive breast cancer.
    Eur J Cancer. 2021;154:217-226.
    PubMed     Abstract available


  8. YAMADA A, Kumamaru H, Shimizu C, Taira N, et al
    Systemic therapy and prognosis of older patients with stage II/III breast cancer: A large-scale analysis of the Japanese Breast Cancer Registry.
    Eur J Cancer. 2021;154:157-166.
    PubMed     Abstract available


  9. LE DU F, Dieras V, Curigliano G
    The role of tyrosine kinase inhibitors in the treatment of HER2+ metastatic breast cancer.
    Eur J Cancer. 2021;154:175-189.
    PubMed     Abstract available


  10. HARTKOPF AD, Brucker SY, Taran FA, Harbeck N, et al
    Disseminated tumour cells from the bone marrow of early breast cancer patients: Results from an international pooled analysis.
    Eur J Cancer. 2021;154:128-137.
    PubMed     Abstract available


  11. ARUN BK, Han HS, Kaufman B, Wildiers H, et al
    Efficacy and safety of first-line veliparib and carboplatin-paclitaxel in patients with HER2- advanced germline BRCA+ breast cancer: Subgroup analysis of a randomised clinical trial.
    Eur J Cancer. 2021;154:35-45.
    PubMed     Abstract available


  12. YUAN Y, Lee JS, Yost SE, Frankel PH, et al
    Phase I/II trial of palbociclib, pembrolizumab and letrozole in patients with hormone receptor-positive metastatic breast cancer.
    Eur J Cancer. 2021;154:11-20.
    PubMed     Abstract available


    June 2021
  13. MUELLER V, Wardley A, Paplomata E, Hamilton E, et al
    Preservation of quality of life in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer treated with tucatinib or placebo when added to trastuzumab and capecitabine (HER2CLIMB trial).
    Eur J Cancer. 2021;153:223-233.
    PubMed     Abstract available


  14. MARME F, Solbach C, Michel L, Schneeweiss A, et al
    Utility of the CPS + EG scoring system in triple-negative breast cancer treated with neoadjuvant chemotherapy.
    Eur J Cancer. 2021;153:203-212.
    PubMed     Abstract available


  15. GUARNERI V, Dieci MV, Griguolo G, Miglietta F, et al
    Trastuzumab-lapatinib as neoadjuvant therapy for HER2-positive early breast cancer: Survival analyses of the CHER-Lob trial.
    Eur J Cancer. 2021;153:133-141.
    PubMed     Abstract available


  16. O'SHAUGHNESSY J, Sousa S, Cruz J, Fallowfield L, et al
    Preference for the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer (PHranceSCa): A randomised, open-label phase II study.
    Eur J Cancer. 2021;152:223-232.
    PubMed     Abstract available


  17. FURLANETTO J, Marme F, Seiler S, Thode C, et al
    Chemotherapy-induced ovarian failure in young women with early breast cancer: Prospective analysis of four randomised neoadjuvant/adjuvant breast cancer trials.
    Eur J Cancer. 2021;152:193-203.
    PubMed     Abstract available


  18. BOTTERI E, Baker JG, Sloan EK
    Response to the letter Re: Carvedilol blocks neural regulation of breast cancer progression in vivo and is associated with reduced breast cancer mortality in patients.
    Eur J Cancer. 2021 Jun 4. pii: S0959-8049(21)00268.
    PubMed    


  19. LYNCH SM, Russell NM, Barron S, Wang CA, et al
    Prognostic value of the 6-gene OncoMasTR test in hormone receptor-positive HER2-negative early-stage breast cancer: Comparative analysis with standard clinicopathological factors.
    Eur J Cancer. 2021;152:78-89.
    PubMed     Abstract available


  20. GELMON KA, Fasching PA, Couch FJ, Balmana J, et al
    Clinical effectiveness of olaparib monotherapy in germline BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: phase IIIb LUCY interim analysis.
    Eur J Cancer. 2021;152:68-77.
    PubMed     Abstract available


    May 2021
  21. WOJTYLA C, Bertuccio P, Wojtyla A, La Vecchia C, et al
    European trends in breast cancer mortality, 1980-2017 and predictions to 2025.
    Eur J Cancer. 2021;152:4-17.
    PubMed     Abstract available


  22. DE SANCTIS R, Vigano A, Torrisi R, Santoro A, et al
    Re: Carvedilol blocks neural regulation of breast cancer progression in vivo and is associated with reduced breast cancer mortality in patients: Sympathetic nervous system activity on breast cancer: the story of migraine.
    Eur J Cancer. 2021 May 27. pii: S0959-8049(21)00266.
    PubMed    


  23. KIM HJ, Noh WC, Nam SJ, Park BW, et al
    Five-year changes in ovarian function restoration in premenopausal patients with breast cancer taking tamoxifen after chemotherapy: An ASTRRA study report.
    Eur J Cancer. 2021;151:190-200.
    PubMed     Abstract available


  24. LUFTNER D, Tesch H, Schmidt M, Hartkopf AD, et al
    Neratinib as extended adjuvant therapy in patients with copositive early breast cancer: German health technology assessment-driven analyses from the ExteNET study.
    Eur J Cancer. 2021;150:268-277.
    PubMed     Abstract available


  25. ROGADO J, Gullon P, Obispo B, Serrano G, et al
    Prolonged SARS-CoV-2 viral shedding in patients with solid tumours and associated factors.
    Eur J Cancer. 2021;148:58-60.
    PubMed    


    April 2021
  26. ETHIER JL, Anderson GM, Austin PC, Clemons M, et al
    Influence of the competing risk of death on estimates of disease recurrence in trials of adjuvant endocrine therapy for early-stage breast cancer: A secondary analysis of MA.27, MA.17 and MA.17R.
    Eur J Cancer. 2021;149:117-127.
    PubMed     Abstract available


    March 2021
  27. PEREZ-GARCIA JM, Llombart-Cussac A, G Cortes M, Curigliano G, et al
    Pembrolizumab plus eribulin in hormone-receptor-positive, HER2-negative, locally recurrent or metastatic breast cancer (KELLY): An open-label, multicentre, single-arm, phase trial.
    Eur J Cancer. 2021;148:382-394.
    PubMed     Abstract available


  28. VILLEGAS SL, Nekljudova V, Pfarr N, Engel J, et al
    Therapy response and prognosis of patients with early breast cancer with low positivity for hormone receptors - An analysis of 2765 patients from neoadjuvant clinical trials.
    Eur J Cancer. 2021;148:159-170.
    PubMed     Abstract available


  29. QUINTANA A, Peg V, Prat A, Moline T, et al
    Immune analysis of lymph nodes in relation to the presence or absence of tumor infiltrating lymphocytes in triple-negative breast cancer.
    Eur J Cancer. 2021;148:134-145.
    PubMed     Abstract available


  30. MICHAELSON-COHEN R, Gabizon-Peretz S, Armon S, Srebnik-Moshe N, et al
    Breast cancer risk and hormone replacement therapy among BRCA carriers after risk-reducing salpingo-oophorectomy.
    Eur J Cancer. 2021;148:95-102.
    PubMed     Abstract available


  31. HOUSSAMI N, Zackrisson S, Blazek K, Hunter K, et al
    Meta-analysis of prospective studies evaluating breast cancer detection and interval cancer rates for digital breast tomosynthesis versus mammography population screening.
    Eur J Cancer. 2021;148:14-23.
    PubMed     Abstract available


  32. JEONG JH, Kim JE, Ahn JH, Jung KH, et al
    Corrigendum to "Leuprorelin combined with letrozole with/without everolimus in ovarian-suppressed premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer: The LEO study [Eur J Canc 144 (2021) 341-350].
    Eur J Cancer. 2021 Mar 7. pii: S0959-8049(21)00071.
    PubMed    


  33. PETRELLI F, Parati MC, Borgonovo K, Cabiddu M, et al
    Adjuvant chemotherapy for pT1abN0M0 triple-negative breast cancer: a systematic review and meta-analysis of published studies.
    Eur J Cancer. 2021;147:151-153.
    PubMed    


  34. LI H, Wang J, Yi Z, Li C, et al
    CDK12 inhibition enhances sensitivity of HER2+ breast cancers to HER2-tyrosine kinase inhibitor via suppressing PI3K/AKT.
    Eur J Cancer. 2021;145:92-108.
    PubMed     Abstract available


  35. PUJOL P, Barberis M, Beer P, Friedman E, et al
    Clinical practice guidelines for BRCA1 and BRCA2 genetic testing.
    Eur J Cancer. 2021;146:30-47.
    PubMed     Abstract available


    February 2021
  36. JIANG M, Li CL, Luo XM, Chuan ZR, et al
    Ultrasound-based deep learning radiomics in the assessment of pathological complete response to neoadjuvant chemotherapy in locally advanced breast cancer.
    Eur J Cancer. 2021;147:95-105.
    PubMed     Abstract available


  37. GILLIS RD, Botteri E, Chang A, Ziegler AI, et al
    Carvedilol blocks neural regulation of breast cancer progression in vivo and is associated with reduced breast cancer mortality in patients.
    Eur J Cancer. 2021;147:106-116.
    PubMed     Abstract available


    January 2021
  38. FURLANETTO J, Mobus V, Schneeweiss A, Rhiem K, et al
    Germline BRCA1/2 mutations and severe haematological toxicities in patients with breast cancer treated with neoadjuvant chemotherapy.
    Eur J Cancer. 2021;145:44-52.
    PubMed     Abstract available


  39. ROBERTSON JFR, Paridaens RJ, Lichfield J, Bradbury I, et al
    Meta-analyses of phase 3 randomised controlled trials of third generation aromatase inhibitors versus tamoxifen as first-line endocrine therapy in postmenopausal women with hormone receptor-positive advanced breast cancer.
    Eur J Cancer. 2021;145:19-28.
    PubMed     Abstract available


  40. DUBSKY P, Tausch C
    Identification of breast cancer patients with pathologic complete response in the breast after neoadjuvant systemic treatment by Pfob et al.
    Eur J Cancer. 2021;143:178-179.
    PubMed    


  41. PATRIKIDOU A, Cathomas R
    Treading carefully in de-escalation for bone-targeted agents - is less more, after all?
    Eur J Cancer. 2021;142:141-142.
    PubMed    


  42. CLEMONS M, Ong M, Stober C, Ernst S, et al
    A randomised trial of 4- versus 12-weekly administration of bone-targeted agents in patients with bone metastases from breast or castration-resistant prostate cancer.
    Eur J Cancer. 2021;142:132-140.
    PubMed     Abstract available


    December 2020
  43. R FERREIRA A, Ferreira S, Lambertini M, Maurer C, et al
    Association between pertuzumab-associated diarrhoea and rash and survival outcomes in patients with HER2-positive metastatic breast cancer: Exploratory analysis from the CLEOPATRA trial.
    Eur J Cancer. 2020;144:351-359.
    PubMed     Abstract available


  44. JEONG JH, Kim JE, Ahn JH, Jung KH, et al
    Leuprorelin combined with letrozole with/without everolimus in ovarian-suppressed premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer: The LEO study.
    Eur J Cancer. 2020;144:341-350.
    PubMed     Abstract available


  45. BATTISTI NML, Reed MWR, Herbert E, Morgan JL, et al
    Bridging the Age Gap in breast cancer: Impact of chemotherapy on quality of life in older women with early breast cancer.
    Eur J Cancer. 2020;144:269-280.
    PubMed     Abstract available


  46. LAKSHMI S, Hughes TA, Priya S
    Exosomes and exosomal RNAs in breast cancer: A status update.
    Eur J Cancer. 2020;144:252-268.
    PubMed     Abstract available


  47. RIBELLES N, Jerez JM, Rodriguez-Brazzarola P, Jimenez B, et al
    Machine learning and natural language processing (NLP) approach to predict early progression to first-line treatment in real-world hormone receptor-positive (HR+)/HER2-negative advanced breast cancer patients.
    Eur J Cancer. 2020;144:224-231.
    PubMed     Abstract available


  48. BOERS J, Venema CM, de Vries EFJ, Hospers GAP, et al
    Serial [(18)F]-FDHT-PET to predict bicalutamide efficacy in patients with androgen receptor positive metastatic breast cancer.
    Eur J Cancer. 2020;144:151-161.
    PubMed     Abstract available


  49. GERRATANA L, Davis AA, Polano M, Zhang Q, et al
    Understanding the organ tropism of metastatic breast cancer through the combination of liquid biopsy tools.
    Eur J Cancer. 2020;143:147-157.
    PubMed     Abstract available


  50. PFOB A, Sidey-Gibbons C, Lee HB, Tasoulis MK, et al
    Identification of breast cancer patients with pathologic complete response in the breast after neoadjuvant systemic treatment by an intelligent vacuum-assisted biopsy.
    Eur J Cancer. 2020;143:134-146.
    PubMed     Abstract available


  51. KOIVULUOMA S, Tervasmaki A, Kauppila S, Winqvist R, et al
    Exome sequencing identifies a recurrent variant in SERPINA3 associating with hereditary susceptibility to breast cancer.
    Eur J Cancer. 2020;143:46-51.
    PubMed     Abstract available


    November 2020
  52. DAFNI U, Martin-Lluesma S, Balint K, Tsourti Z, et al
    Efficacy of cancer vaccines in selected gynaecological breast and ovarian cancers: A 20-year systematic review and meta-analysis.
    Eur J Cancer. 2020;142:63-82.
    PubMed     Abstract available


  53. WYLD L, Reed MWR, Morgan J, Collins K, et al
    Bridging the age gap in breast cancer. Impacts of omission of breast cancer surgery in older women with oestrogen receptor positive early breast cancer. A risk stratified analysis of survival outcomes and quality of life.
    Eur J Cancer. 2020;142:48-62.
    PubMed     Abstract available


  54. COTTU P, Coudert B, Perol D, Doly A, et al
    Evolution in the real-world therapeutic strategies in more than 20,000 women with breast cancer having received human epidermal growth factor receptor 2-targeted treatments: Results from the french personalized reimbursement model database (2011-2018)
    Eur J Cancer. 2020;141:209-217.
    PubMed     Abstract available


  55. HUBEL K, Kron F, Lux MP
    Biosimilars in oncology: Effects on economy and therapeutic innovations.
    Eur J Cancer. 2020;139:10-19.
    PubMed     Abstract available


    October 2020
  56. STRADELLA A, Del Valle J, Rofes P, Vargas-Parra G, et al
    ERCC3, a new ovarian cancer susceptibility gene?
    Eur J Cancer. 2020;141:1-8.
    PubMed     Abstract available


  57. FINK MK
    Survival in metastatic breast cancer in the ESME study and the ATRESS effect.
    Eur J Cancer. 2020 Oct 3. pii: S0959-8049(20)30495.
    PubMed    


  58. DELUCHE E, Antoine A, Bachelot T, Robain M, et al
    A response letter to comments on "Contemporary outcomes of metastatic breast cancer among 22,000 women from the multicentre ESME cohort 2008-2016".
    Eur J Cancer. 2020 Oct 3. pii: S0959-8049(20)30490.
    PubMed    


    September 2020
  59. SALVADOR-COLOMA C, Santaballa A, Sanmartin E, Calvo D, et al
    Immunosuppressive profiles in liquid biopsy at diagnosis predict response to neoadjuvant chemotherapy in triple-negative breast cancer.
    Eur J Cancer. 2020;139:119-134.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Breast Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: